Vericel (VCEL) Price & Analysis

Compare

628 Followers

VCEL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$33.09 - $63.00

Previous CloseN/A

Volume83.17K

Average Volume (3M)568.62K

Market Cap

$1.80B

Enterprise Value$2.13B

Total Cash (Recent Filing)$116.88M

Total Debt (Recent Filing)$99.76M

Price to Earnings (P/E)285.7

Beta1.17

Next Earnings

Nov 06, 2025

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding50,342,968

10 Day Avg. Volume679,207

30 Day Avg. Volume568,616

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.18

Enterprise Value/Revenue8.54

Enterprise Value/Gross Profit11.62

Enterprise Value/Ebitda181.41

Forecast

1Y Price Target

$58.57

Price Target Upside64.38% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Growth PotentialMACI is expected to become a billion-dollar franchise, indicating strong potential for growth.

Market DemandThe expansion of the MACI surgeon customer base and growth in biopsies suggests increasing demand and market penetration.

Product DevelopmentFDA clearance for the Phase 3 MASCOT study with MACI ankle indicates progress in product development and potential future opportunities.

Bears Say

Guidance AdjustmentThe price target has been lowered to $61 from $67 as comparative multiples for the high-growth comp group have retracted.

Revenue ConcernsShare pressure has been driven by concerns surrounding the revenue acceleration required to meet Street estimates.

Vericel News

Vericel price target lowered to $58 from $61 at Canaccord

Canaccord lowered the firm’s price target on Vericel (VCEL) to $58 from $61 and keeps a Buy rating...

3d ago

VCEL

Vericel reports Q2 EPS (1c), consensus (4c)

Reports Q2 revenue $63.2M, consensus $64.49M. “The Company delivered another quarter of solid financial and business results in...

3d ago

VCEL

Vericel reaffirms FY25 MACI revenue growth in low 20% range

Reaffirmed MACI full-year revenue growth in the low 20% range; Updated Burn Care revenue guidance for the second...

3d ago

VCEL

Vericel price target lowered to $51 from $58 at BTIG

BTIG lowered the firm’s price target on Vericel (VCEL) to $51 from $58 and keeps a Buy rating...

21d ago

VCEL

Vericel Corporation Reports Strong Q2 2025 Earnings

Vericel Corporation (($VCEL)) has held its Q2 earnings call. Read on for the main highlights of the call....

2d ago

VCEL

Vericel’s Strong Growth Potential and Strategic Positioning Drive Buy Rating

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Vericel, with a...

3d ago

VCEL

Vericel Corporation Reports Strong Q2 2025 Results

Vericel Corporation ( ($VCEL) ) has released its Q2 earnings. Here is a breakdown of the information Vericel...

3d ago

VCEL

Vericel’s Strong Growth and Operational Efficiency Justify Buy Rating Despite Slight Performance Miss

Vericel, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD...

3d ago

VCEL

VCEL Upcoming Earnings Report: What to Expect?

Vericel Corporation (VCEL) is scheduled to report 2nd quarter earnings on 07/31/2025, before the market opens. Regarding Q2...

6d ago

VCEL

Vericel Poised for Strong Growth: Buy Rating Affirmed on Robust MACI Expansion and Burn Care Improvements

In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Vericel, with a...

6d ago

VCEL

Promising Growth for Vericel with MACI Arthro Technique Boosting Market Position

Analyst Caitlin Cronin of Canaccord Genuity maintained a Buy rating on Vericel (VCEL – Research Report), retaining the...

2M ago

VCEL

Vericel management to meet with Stephens

Meeting to be held in Minneapolis on May 19 and in Milwaukee on May 20 hosted by Stephens....

3M ago

VCEL

Vericel’s Strong Buy Rating Amid Adjusted Guidance and Robust Valuation

Caitlin Cronin, an analyst from Canaccord Genuity, maintained the Buy rating on Vericel (VCEL – Research Report). The...

3M ago

VCEL

Vericel management to meet with Truist

Meeting to be held in Boston on May 12 hosted by Truist. Published first on TheFly – the...

3M ago

VCEL

VCEL FAQ

What was Vericel Corp’s price range in the past 12 months?

Vericel Corp lowest stock price was $33.09 and its highest was $63.00 in the past 12 months.

What is Vericel Corp’s market cap?

Vericel Corp’s market cap is $1.80B.

When is Vericel Corp’s upcoming earnings report date?

Vericel Corp’s upcoming earnings report date is Nov 06, 2025 which is in 95 days.

How were Vericel Corp’s earnings last quarter?

Vericel Corp released its earnings results on Jul 31, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.032 by $0.022.

Is Vericel Corp overvalued?

According to Wall Street analysts Vericel Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vericel Corp pay dividends?

Vericel Corp does not currently pay dividends.

What is Vericel Corp’s EPS estimate?

Vericel Corp’s EPS estimate is >-0.01.

How many shares outstanding does Vericel Corp have?

Vericel Corp has 50,342,968 shares outstanding.

What happened to Vericel Corp’s price movement after its last earnings report?

Vericel Corp reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.032. Following the earnings report the stock price went down -14.068%.

Which hedge fund is a major shareholder of Vericel Corp?

Currently, no hedge funds are holding shares in VCEL

Vericel Stock Smart Score

Neutral

Fundamentals

Return on Equity

2.59%

Trailing 12-Months

Asset Growth

15.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vericel Corp

Vericel Corporation (VCEL) is a leading biotechnology company specializing in advanced cell therapies for the treatment of patients with severe diseases and conditions. The company primarily operates in the regenerative medicine sector, focusing on developing and commercializing innovative therapies that repair and regenerate damaged tissues. Vericel's core products include MACI, an autologous cellularized scaffold product for the treatment of cartilage defects in the knee, and Epicel, a permanent skin replacement for patients with severe burns.

Vericel (VCEL) Earnings & Revenues

VCEL Earnings Data >

VCEL Company Deck

VCEL Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The call reflects strong overall performance with significant revenue and profitability growth, especially in the MACI and Burn Care segments. However, challenges in Epicel revenue conversion and adjusted guidance for the Burn Care segment present areas of concern.Read More>

VCEL Stock 12 Month Forecast

Average Price Target

$58.57

▲(64.38%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"$34","51":"$51","68":"$68","42.5":"$42.5","59.5":"$59.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$67.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$58.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$51.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,42.5,51,59.5,68],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.63,38.043076923076924,40.456153846153846,42.86923076923077,45.2823076923077,47.69538461538461,50.10846153846154,52.52153846153846,54.934615384615384,57.347692307692306,59.76076923076923,62.173846153846156,64.58692307692307,{"y":67,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.63,37.394615384615385,39.159230769230774,40.923846153846156,42.68846153846154,44.45307692307692,46.21769230769231,47.98230769230769,49.74692307692308,51.511538461538464,53.276153846153846,55.04076923076923,56.80538461538462,{"y":58.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.63,36.8123076923077,37.994615384615386,39.17692307692308,40.35923076923077,41.541538461538465,42.723846153846154,43.90615384615385,45.08846153846154,46.27076923076923,47.45307692307692,48.635384615384616,49.81769230769231,{"y":51,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.03,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.52,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.65,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.91,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.54,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.29,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.08,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >